Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naldemedine in OIC with non-malignant chronic pain (COMPOSE-2)
NCT01993940Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Nov 2013
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in opioid-induced constipation (OIC) comparing Naldemedine with Placebo (2 arms). Primary endpoint: Percentage of Participants With a Spontaneous Bowel Movement (SBM) Response at 12 weeks. Started Nov 2013; status: completed.
02
Drugs
naldemedine
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on NCT01993940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01993940.